Irvine, California, USA, November 18, 2026
Masimo Corporation, a Danaher company specialising in patient monitoring and diagnostic technologies, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for smartSedLine™, its next-generation brain function monitoring solution designed to support improved assessment of patients during anesthesia. The technology is intended to help clinicians understand changes in brain activity more quickly and consistently, supporting more individualised decisions about the depth of sedation throughout surgical procedures. The newly cleared system features an enhanced Patient State Index (PSi) algorithm, which provides faster responses during anesthesia induction and more stable measurements when electroencephalography (EEG) signals are weak. The development represents an important advancement in perioperative brain monitoring, particularly for elderly patients and individuals at increased risk of complications associated with anesthesia. According to Masimo, this is the company’s seventh FDA clearance in 2026, highlighting its continued development of patient monitoring technologies.
Enhanced PSi Algorithm Improves Brain Activity Monitoring
The newly cleared smartSedLine system builds on Masimo’s established SedLine® brain function monitoring platform. It is designed to translate complex electrical activity recorded through electroencephalography (EEG) into information that clinicians can interpret more easily during anesthesia. EEG monitoring measures electrical signals generated by the brain and can help healthcare professionals assess changes in brain activity associated with different levels of sedation. However, interpreting raw EEG waveforms can be challenging and often requires specialised clinical training. Masimo’s system addresses this challenge through tools such as the Patient State Index (PSi) and Density Spectral Array (DSA). The PSi algorithm uses multiple processing engines to analyse EEG power and patterns before calculating a numerical index that helps clinicians evaluate a patient’s sedation state. With smartSedLine, Masimo has introduced an enhanced algorithm intended to provide more responsive and consistent information. The improvement is particularly relevant during anesthesia induction, when patients transition from an awake state to unconsciousness and brain activity can change rapidly. Faster monitoring responses may help clinicians recognise these changes earlier and adjust anesthesia management according to individual patient requirements.
Technology Designed for More Individualised Anesthesia Care
A key feature of smartSedLine is its ability to provide faster PSi responses during induction and improved stability under low-power EEG conditions. Low-power EEG signals can make brain activity interpretation more difficult, potentially affecting the consistency of monitoring information. The enhanced algorithm is designed to maintain more reliable measurements under these conditions, supporting clinicians in assessing sedation depth throughout surgical procedures. Masimo believes these improvements could be particularly valuable for elderly patients, high-risk surgical patients and individuals with vulnerable brains, who may respond differently to anesthetic medicines. Every patient has individual physiological characteristics and may require different anesthesia management strategies. By providing more responsive information about brain function, smartSedLine aims to support clinical decision-making and help healthcare professionals tailor anesthetic administration. Masimo’s Chief Medical Officer, Dr. Basil Matta, highlighted that understanding individual patient responses is important for optimising sedation depth and informing perioperative care. The company also stated that earlier insight into sedation changes may help clinicians support hemodynamic stability in vulnerable patients. However, the technology is intended to support clinical assessment and does not replace the judgement of trained anesthesia professionals.
New Monitoring Module Integrates With Masimo Root Platform
The smartSedLine solution will be available through a new smartSedLine module and dedicated EEG sensor. Similar to the previous SedLine module, the new system is designed for plug-and-play connectivity with compatible Masimo monitoring platforms, including the Root® patient monitoring and connectivity platform. When used with Root, smartSedLine can operate alongside Masimo’s O3® Regional Oximetry technology, which monitors regional oxygen saturation in the brain and other tissues. Combining EEG-based brain function monitoring with regional oxygenation measurements can provide clinicians with complementary information during perioperative care. While smartSedLine focuses on electrical brain activity and sedation assessment, O3 technology provides information about tissue oxygenation. Together, these technologies form what Masimo describes as a comprehensive Brain Health Platform intended to support a broader understanding of a patient’s neurological and physiological condition during surgery. The integration is designed to make relevant monitoring information more accessible to clinicians using compatible equipment.
The FDA 510(k) clearance marks another regulatory milestone for Masimo’s patient monitoring portfolio and reflects growing interest in technologies that support brain health during anesthesia. The company continues to develop solutions intended to improve the interpretation of physiological signals and help clinicians make informed decisions in complex care environments. smartSedLine is a monitoring technology, not an anesthetic drug or treatment for neurological disease. Its clinical value will depend on how healthcare professionals integrate the additional monitoring information into patient care and anesthesia management. The clearance nevertheless represents an important development in EEG-based brain monitoring and individualised anesthesia management, with potential applications in operating rooms and other perioperative care settings.
Source: Masimo press release



